Barclays upgraded Astrana Health to Overweight from Equal Weight and raised its price target to $50 from $37. The firm cited materially improved outlook for value-based care, driven by stabilizing cost trends and a more favorable 2027 Medicare Advantage rate outcome. Astrana Health also has room for multiple expansion as it integrates Prospect and accelerates full-risk membership growth. In its fiscal first quarter 2026 results, the company reported total revenue of $965.1 million, up 56% year over year, adjusted EBITDA of $66.3 million, up 82%, and free cash flow of $64.1 million, up 372%.
Astrana Health IncBarclays upgraded to Overweight and raised price target to $50, citing improved outlook and strong Q1 results.